CompuGroup Medical SE & Co. KGaA (CMPVF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CompuGroup Medical SE & Co. KGaA (CMPVF) trades at $33.66 with AI Score 48/100 (Grade C). CompuGroup Medical SE & Co. KGaA provides healthcare IT solutions globally, operating across ambulatory, pharmacy, hospital, and consumer health segments. Market cap: $1.74B, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for CMPVF: CMPVF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CMPVF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CMPVF: the 1 perspectives are evenly split.
How is this calculated? →CompuGroup Medical SE & Co. KGaA (CMPVF) Healthcare & Pipeline Overview
CompuGroup Medical SE & Co. KGaA, a German-based healthcare IT provider, develops and distributes software solutions for various healthcare segments including ambulatory, pharmacy, and hospital settings. With a focus on digitalization and connectivity, the company serves a global customer base, facing competition in a rapidly evolving healthcare technology landscape.
What Is the Investment Thesis for CMPVF?
CompuGroup Medical presents a mixed investment case. The company's established presence in the healthcare IT sector and diverse product portfolio offer stability. The company's P/E ratio is high at 89.71, while its profit margin is relatively low at 1.5%. Growth catalysts include the increasing adoption of digital health solutions and expansion into new geographic markets. However, the company faces risks related to competition, regulatory changes, and integration of acquired businesses. Investors should carefully weigh these factors before considering an investment in CMPVF.
Based on FMP financials and quantitative analysis
CMPVF Key Highlights
- CompuGroup Medical operates in four segments: Ambulatory Information Systems (AIS), Pharmacy Information Systems (PCS), Hospital Information Systems (HIS), and Consumer & Health Management Information Systems (CHS), demonstrating a diversified revenue stream.
- The company's gross margin of 83.6% indicates strong pricing power and efficient cost management in its software and IT solutions.
- CompuGroup Medical serves a global customer base, including healthcare providers, pharmaceutical companies, health insurance companies, and consumers, reflecting a broad market reach.
- The company has a market capitalization of $1.74B, positioning it as a significant player in the healthcare IT sector.
- CompuGroup Medical offers a dividend yield of 0.22%, providing a modest income stream for investors.
Who Are CMPVF's Competitors?
CMPVF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BITGF Biotage AB (publ) | $15.01 | +0.00% | $1.20B | 52 |
| BTTAY Biotest AG | $24.21 | -0.10% | $1.88B | 48 |
| DGWPF Drägerwerk AG & Co. KGaA | $72.00 | -13.25% | $1.35B | 47 |
| DWRKF Drägerwerk AG & Co. KGaA | $543.70 | +0.00% | $1.75B | 49 |
| KKPCF Kaken Pharmaceutical Co., Ltd. | $26.78 | +3.00% | $1.01B | 56 |
| CARL CARLSMED, INC. | $11.90 | +4.94% | $323.50M | 70 |
| HNGE Hinge Health, Inc. | $89.42 | +6.39% | $6.92B | 68 |
| VRHI Veri Medtech Holdings Inc. | $1.95 | +0.00% | $39.09M | 67 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CMPVF's Key Strengths?
- Comprehensive product portfolio across multiple healthcare segments
- Strong presence in the European healthcare IT market
- Established customer base and long-term relationships
- Expertise in healthcare regulations and compliance
What Are CMPVF's Weaknesses?
- Relatively low profit margin compared to peers
- Dependence on the European market
- Limited presence in the US healthcare IT market
- High P/E ratio
What Could Drive CMPVF Stock Higher?
- Increasing adoption of digital health solutions and electronic health records driving demand for CompuGroup Medical's products.
- Expansion into new geographic markets, particularly in Asia-Pacific, driving revenue growth.
- Potential acquisitions of complementary businesses to expand product portfolio and market share.
- Development and launch of new cloud-based solutions and services.
- Leveraging data analytics and AI to improve healthcare outcomes and efficiency.
What Are the Key Risks for CMPVF?
- Financial-distress signal — its Altman Z-Score of 1.46 sits in the distress zone (elevated bankruptcy risk).
- Rich valuation — a P/E of 263.6 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Intense competition from established healthcare IT providers.
- Regulatory changes and data privacy concerns impacting the healthcare IT market.
- Cybersecurity threats and data breaches compromising sensitive patient data.
- Economic downturns and healthcare budget cuts reducing demand for healthcare IT solutions.
- Integration risks associated with acquired businesses.
What Are the Growth Opportunities for CMPVF?
- Expansion in Telehealth Solutions: CompuGroup Medical can expand its telehealth solutions to capitalize on the growing demand for remote healthcare services. The telehealth market is projected to reach $55 billion by 2027, driven by factors such as increased access to care, cost savings, and convenience. CompuGroup Medical can leverage its existing IT infrastructure and customer base to offer integrated telehealth solutions to healthcare providers and patients, enhancing its market position.
- Strategic Acquisitions: CompuGroup Medical can pursue strategic acquisitions to expand its product portfolio and geographic reach. The healthcare IT market is fragmented, with numerous small and medium-sized players offering niche solutions. CompuGroup Medical can acquire companies with complementary technologies or market access to accelerate its growth and strengthen its competitive position. These acquisitions can provide access to new markets, technologies, and talent, driving long-term value creation.
- Cloud-Based Solutions: CompuGroup Medical can transition its software solutions to cloud-based platforms to improve scalability, flexibility, and cost-effectiveness. The cloud computing market in healthcare is projected to reach $77.9 billion by 2028, driven by factors such as data security, interoperability, and remote access. CompuGroup Medical can leverage cloud technologies to offer subscription-based services, reduce IT infrastructure costs, and enhance customer satisfaction.
- Data Analytics and AI: CompuGroup Medical can leverage data analytics and artificial intelligence (AI) to improve healthcare outcomes and efficiency. The healthcare analytics market is projected to reach $75 billion by 2028, driven by factors such as the need for improved decision-making, personalized medicine, and population health management. CompuGroup Medical can develop AI-powered tools to analyze patient data, predict disease outbreaks, and optimize treatment plans, providing valuable insights to healthcare providers and patients.
- International Expansion: CompuGroup Medical can expand its presence in emerging markets to capitalize on the growing demand for healthcare IT solutions. The healthcare IT market in Asia-Pacific is projected to grow at a CAGR of 12% from 2023 to 2028, driven by factors such as increasing healthcare expenditure, government initiatives, and technological advancements. CompuGroup Medical can leverage its expertise and product portfolio to offer customized solutions to healthcare providers in emerging markets, driving revenue growth and market share.
What Opportunities Does CMPVF Have?
- Expansion into emerging markets with growing healthcare expenditure
- Increased adoption of cloud-based healthcare solutions
- Leveraging data analytics and AI to improve healthcare outcomes
- Strategic acquisitions to expand product portfolio and geographic reach
What Threats Does CMPVF Face?
- Intense competition from established healthcare IT providers
- Regulatory changes and data privacy concerns
- Cybersecurity threats and data breaches
- Economic downturns and healthcare budget cuts
What Are CMPVF's Competitive Advantages?
- High Switching Costs: Customers face significant costs and disruption when switching to a different healthcare IT provider, creating customer stickiness.
- Integrated Solutions: CompuGroup Medical offers a comprehensive suite of integrated solutions across various healthcare segments, providing a competitive advantage.
- Established Customer Base: The company has a large and established customer base, providing a stable revenue stream and opportunities for cross-selling.
- Regulatory Expertise: CompuGroup Medical has deep expertise in healthcare regulations and compliance, which is a critical factor in the healthcare IT market.
What Does CMPVF Do?
Founded in 1987 and headquartered in Koblenz, Germany, CompuGroup Medical SE & Co. KGaA (CMPVF) has evolved into a leading provider of software and IT solutions for the healthcare sector worldwide. The company operates through four key segments: Ambulatory Information Systems (AIS), Pharmacy Information Systems (PCS), Hospital Information Systems (HIS), and Consumer & Health Management Information Systems (CHS). The AIS segment offers practice management software and electronic medical records for physicians and medical centers. The PCS segment provides software for pharmacies, focusing on administrative and billing processes. The HIS segment delivers clinical and administrative solutions for hospitals and rehabilitation centers. The CHS segment provides IT security services, data-based product offers, software interface for sharing of information, clinical decision-making support, and medication and treatment databases. CompuGroup Medical's solutions support healthcare providers in streamlining operations, improving patient care, and managing administrative tasks. The company's global reach extends to serving pharmaceutical companies, health insurance providers, and consumers. CompuGroup Medical changed its name from CompuGroup Medical SE to CompuGroup Medical SE & Co. KGaA in June 2020, reflecting its ongoing evolution and commitment to the healthcare IT market. The company's focus on innovation and digital transformation positions it to address the evolving needs of the healthcare industry.
What Products and Services Does CMPVF Offer?
- Develops and sells software for doctors' offices and medical centers.
- Provides software solutions for pharmacies to manage prescriptions and inventory.
- Offers clinical and administrative systems for hospitals and rehabilitation facilities.
- Creates IT solutions for healthcare providers, insurance companies, and patients.
- Provides IT security services for healthcare data protection.
- Offers data-based products and software interfaces for information sharing.
- Develops consumer portals and mobile apps for health management.
How Does CMPVF Make Money?
- Software Licensing: Generates revenue through the sale and licensing of its software products to healthcare providers and institutions.
- Subscription Services: Offers subscription-based access to its cloud-based solutions and services.
- IT Services: Provides IT consulting, implementation, and support services to its customers.
- Data Analytics: Generates revenue from data analytics services, providing insights and reports to healthcare organizations.
What Industry Does CMPVF Operate In?
CompuGroup Medical operates in the healthcare IT sector, which is experiencing rapid growth due to the increasing adoption of digital health solutions, electronic health records, and telehealth services. The market is competitive, with key players including BITGF (Allscripts Healthcare Solutions), BTTAY (Cerner Corporation), and DGWPF (Teladoc Health). CompuGroup Medical's focus on providing integrated solutions across various healthcare segments positions it to capitalize on the growing demand for digital healthcare technologies. The global healthcare IT market is projected to reach $390 billion by 2024, driven by factors such as government initiatives, technological advancements, and the need for improved healthcare efficiency.
Who Are CMPVF's Key Customers?
- Registered Physicians and Medical Care Centers
- Pharmacies
- Acute Care Hospitals and Rehabilitation Centers
- Health Insurance Companies
- Pharmaceutical Companies
Company Profile
CompuGroup Medical SE & Co. KGaA operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Koblenz, DE. The company is led by CEO Daniel Gotthardt. CMPVF has traded publicly since 2013.
ROE 1%Key Financial Metrics
Return on equity for CompuGroup Medical SE & Co. KGaA stands at 0.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.2%, showing how much profit it generates from its asset base. CMPVF trades at a trailing price-to-earnings ratio of 263.62, above the Healthcare sector average of ~23x. Its free cash flow yield is 7.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.12 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.4%, the inverse of the P/E and a quick read on earnings relative to price.
CMPVF Valuation & Market Position
With a $1.74B market cap, CompuGroup Medical SE & Co. KGaA sits in the small-cap segment of the market. Relative to its peer group, CMPVF's quantitative score of 48/100 is roughly in line with the peer average of 50/100.
Quarterly Financial Performance: CompuGroup Medical SE & Co. KGaA
Revenue for CompuGroup Medical SE & Co. KGaA came in at $291.2M during Q2 2025, a 1.8% improvement versus the preceding quarter. The company recorded net income of $5.2M, with diluted EPS of $0.10. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, CMPVF averaged $0.09 in diluted EPS.
F-Score 6/9Financial Health
CompuGroup Medical SE & Co. KGaA's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.46 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project CompuGroup Medical SE & Co. KGaA revenue of about $1.39B for fiscal 2026, with EPS near $2.16.
CMPVF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Comprehensive product portfolio across multiple healthcare segments
- Strong presence in the European healthcare IT market
- Established customer base and long-term relationships
- Expertise in healthcare regulations and compliance
Bear Case
- Relatively low profit margin compared to peers
- Dependence on the European market
- Limited presence in the US healthcare IT market
- High P/E ratio
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $291M | $5M | $0.10 |
| Q1 2025 | $286M | $11M | $0.21 |
| Q4 2024 | $309M | -$6M | -$0.13 |
| Q3 2024 | $283M | $9M | $0.17 |
Based on FMP financials and quantitative analysis
CMPVF Latest News
No recent news available for CMPVF.
CMPVF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CMPVF.
Price Targets
Wall Street price target analysis for CMPVF.
CMPVF MoonshotScore
What does this score mean?
The MoonshotScore rates CMPVF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Daniel Gotthardt
CEO
Daniel Gotthardt serves as the CEO of CompuGroup Medical SE & Co. KGaA. His leadership is pivotal in guiding the company's strategic direction and operational execution. Information regarding his specific educational background and prior roles is not available in the provided data. However, as CEO, he is responsible for overseeing the company's global operations and driving its growth strategy in the healthcare IT market.
Track Record: As CEO of CompuGroup Medical, Daniel Gotthardt is responsible for leading the company's efforts to develop and deliver innovative healthcare IT solutions to customers worldwide. Specific achievements and milestones under his leadership are not detailed in the provided data. His focus is on driving the company's growth, enhancing its market position, and ensuring its long-term success in the rapidly evolving healthcare IT landscape.
CMPVF OTC Market Information
The OTC Other tier, where CompuGroup Medical SE & Co. KGaA trades, represents the lowest tier of the OTC market. Companies in this tier may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. These companies often have limited operating history, may be thinly traded, and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and potential for fraud or manipulation.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity and trading volume on the OTC market
- Lack of transparency and limited financial disclosure
- Potential for price manipulation and fraud
- Higher risk of financial distress or bankruptcy
- Limited regulatory oversight and investor protection
- Verify the company's registration and legal status
- Obtain and review the company's financial statements (if available)
- Assess the company's business model and competitive landscape
- Evaluate the company's management team and track record
- Research the company's history and any past legal or regulatory issues
- Understand the risks associated with investing in OTC stocks
- Consult with a financial advisor before making any investment decisions
- The company has been in operation since 1987.
- CompuGroup Medical serves a global customer base.
- The company operates in a regulated industry (healthcare IT).
- CompuGroup Medical has a market capitalization of $1.74B.
Common Questions About CMPVF (Healthcare)
What does CompuGroup Medical SE & Co. KGaA do?
CompuGroup Medical SE & Co. KGaA is a global healthcare IT provider that develops and sells software and IT solutions for various healthcare segments. These include ambulatory care, pharmacy services, hospital information systems, and consumer health management. The company's products and services support healthcare providers, insurers, and patients by streamlining operations, improving patient care, and facilitating data-driven decision-making. CompuGroup Medical's integrated solutions aim to enhance connectivity and efficiency across the healthcare ecosystem.
What do analysts say about CMPVF stock?
Analyst sentiment on CMPVF stock is currently mixed, reflecting the company's position in the evolving healthcare IT landscape. Key valuation metrics, such as the high P/E ratio of 263.6, suggest that the stock may be overvalued relative to its earnings. Growth considerations include the company's expansion into new markets and its focus on cloud-based solutions. Investors should conduct their own due diligence and consider their individual risk tolerance before making any investment decisions regarding CMPVF.
What are the main risks for CMPVF?
CompuGroup Medical faces several risks, including intense competition in the healthcare IT market, regulatory changes and data privacy concerns, cybersecurity threats, and economic downturns. The company's relatively low profit margin of 1.5% also poses a risk to its financial performance. Additionally, the company's reliance on the European market and its limited presence in the US market could limit its growth potential. Investors should carefully consider these risks before investing in CMPVF.
What are the key factors to evaluate for CMPVF?
CompuGroup Medical SE & Co. KGaA (CMPVF) holds an AI score of 48/100 (low). P/E: 263.6x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does CMPVF data refresh on this page?
CMPVF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CMPVF's recent stock price performance?
CompuGroup Medical SE & Co. KGaA (CMPVF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive product portfolio across multiple healthcare segments. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CMPVF overvalued or undervalued right now?
CompuGroup Medical SE & Co. KGaA (CMPVF) trades at 263.6x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CMPVF?
Before investing in CompuGroup Medical SE & Co. KGaA (CMPVF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis pending may provide further insights.